Best Cell Therapy Companies in Massachusetts, United States
The 54 best Cell Therapy companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ziopharm Oncology.
Ranked: Best Cell Therapy companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Ziopharm Oncology Develops immunotherapies for the treatment of cancer and autoimmune diseases | $377M | 82 mo ago | 36 | 2003 | Kevin Boyle CEO | 160 patents Isophosphoramide mustard salt prodrugs for oral cancer therapy, especially glioblastoma. | — |
| 2 | Obsidian Therapeutics Developer of engineered cell and gene therapies for multiple diseases | $325M | 27 mo ago | 80 80 → 105 (+31%) · sector median +22% | 2015 | Michael Gilman CEO | 158 patents Engineered cytokine fusion proteins and regulated cell‑therapy platforms for cancer immunotherapy | — |
| 3 | Be Bio Developer of B cell therapies for multiple therapeutic areas 50Funding top 22%Moat top 31%Market top 48%Global bottom 36% All 4 signals ▾Fundingtop 22% Moattop 31% Markettop 48% Globalbottom 36% Funding: Raised $264M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $264M | 18 mo ago | 103 | 2020 | — | — | — |
| 4 | Abcuro Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer 42Funding top 22%Moat top 28%Growth top 35%Patents top 35% All 9 signals ▾Fundingtop 22% Moattop 28% Growthtop 35% Patentstop 35% Innovationtop 36% Globalbottom 42% Marketbottom 32% Techbottom 19% Newsbottom 17% Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $252M | 17 mo ago | 24 24 → 40 (+67%) · sector median +22% | 2015 | — | 48 patents Therapeutic anti‑KLRG1 antibodies for treating immune‑cell malignancies and autoimmune diseases | — |
| 5 | Rubius Therapeutics Genetically modifying hematopoietic stem cells to create RBC therapeutics in metabolic deficiencies… | $245M | 90 mo ago | 256 | 2015 | — | 244 patents Patents concentrated in chemistry & materials | — |
| 6 | Blue Rock Therapeutics Stem cell therapies for cardiovascular and neurological diseases | $225M | 115 mo ago | 138 | 2016 | — | — | — |
| 7 | Ensoma Developer of in vivo hematopoietic stem cell engineering for genomic medicine | $205M | 38 mo ago | 52 52 → 51 (-2%) · sector median +22% | 2019 | — | 62 patents Adenoviral gene‑therapy vectors enabling multi‑lineage therapeutic expression and stem‑cell mobilization | — |
| 8 | Garuda Developer of stem cell-based therapies to treat multiple diseases | $182M | 21 mo ago | 44 | 2021 | David Scadden Co-Founder | 2 patents Patents concentrated in computing, sensing & instrumentation | — |
| 9 | TScan Therapeutics Developer of T cell therapies to harness the immune system against cancer | $180M | 65 mo ago | 154 154 → 151 (-2%) · sector median +22% | 1995 | — | 162 patents Targeted binding protein therapeutics for cancer immunotherapy and hematologic malignancies | 1 launch · 1 partnership |
| 10 | TCR2 Therapeutics Developer of pharmaceutical products that focused on engineering T cells for cancer therapy | $170M | 99 mo ago | 58 | 2015 | — | 199 patents Engineering TCR fusion proteins for adoptive cell immunotherapy | — |
| 11 | Semma Therapeutics Provider of bio-artificial pancreas for Type 1 Diabetes treatment | $158M | 88 mo ago | 58 | 2015 | — | — | — |
| 12 | Magenta Therapeutics Developer of stem cell-based therapies for autoimmune disease, genetics blood disorders and cancer | $150M | 62 mo ago | 75 | 2016 | — | 347 patents Hematopoietic stem cell mobilization and targeted antibody‑drug conjugates for transplantation | — |
| 13 | Cellino Developer of autologous cell therapies | $125M | 21 mo ago | 43 43 → 107 (+149%) · sector median +22% | 2017 | Matthias Wagner Co-Founder & CTO | — | 1 award |
| 14 | Histogenics Developer of restorative cell therapies for orthopedic diseases | $116M | 118 mo ago | 84 | 2000 | — | 121 patents Adhesive scaffolds and porous matrices for articular cartilage regeneration. | — |
| 15 | Abata Developer of cell therapies for autoimmune and inflammatory disease | $110M | 23 mo ago | 50 | 2021 | Samantha Singer President & Chief Executive Officer | — | — |
| 16 | Clade Developer of stem cell-derived therapies for cancer treatment | $87M | 56 mo ago | 13 | 2020 | Leandro Vetcher Co-Founder | — | — |
| 17 | Stylus Medicine Developer of gene-based therapeutics for multiple diseases | $85M | 14 mo ago | 21 | 2022 | — | — | — |
| 18 | Faze Medicines Developer of therapeutic solutions for the treatment of amyotrophic lateral sclerosis | $81M | 67 mo ago | 24 | 2019 | Mike Rosen Co-Founder | — | — |
| 19 | Marengo Developer of cell therapy for the treatment of cancer | $80M | 56 mo ago | 38 | 2015 | Zhen Su CEO | — | 1 award |
| 20 | OvaScience Developer of new fertility treatments for women | $77M | 159 mo ago | 19 | 2011 | Chris Kroeger CEO | 43 patents Reproductive biotech: anti‑VASA antibodies and in‑vitro oocyte generation from ovarian culture | — |
| 21 | GCTx Developer of a synthetic biology platform for cell programming | $75M | 21 mo ago | 15 | 2019 | Cory Smith Scientific Co-Founder and Head of Discovery Platforms | — | 2 job openings · 1 award |
| 22 | RootPath Genomics Developer of immunotherapy platform for the treatment of cancer | $68M | 58 mo ago | 16 | 2017 | — | 66 patents High‑throughput T‑cell receptor gene assembly and paired immunoreceptor cloning technologies | — |
| 23 | HebeCell Developer of cell therapies for multiple diseases | $53M | 58 mo ago | 20 | 2016 | Allen Feng Founder | 21 patents Stem cell differentiation and manufacturing of retinal and hematopoietic therapeutic cells | — |
| 24 | Abpro Developer of antibody therapies for cancer and infectious diseases | $42M | 51 mo ago | 24 24 → 36 (+50%) · sector median +22% | 2007 | Ian Chan Co-Founder & CEO | 28 patents Multispecific therapeutic antibodies for cancer and eye disease targeting VEGF, ANG2, HER2, CD3, claudin‑18.2 | — |
| 25 | Vericel Corporation Developer of autologous stem cell therapies | $40M | 172 mo ago | 36 | 1989 | — | 26 patents Regenerative cartilage repair using biomaterial scaffolds, cell therapies, and delivery devices. | — |
| 26 | Pervasis Therapeutics KILO303: Official site for online slot games and betting | $40M | 188 mo ago | 18 | 2003 | — | — | — |
| 27 | Kernal Biologics Developer of mRNA therapeutics for immuno-oncology using deep learning technology | $35M | 9 mo ago | 18 18 → 22 (+22%) · sector median +22% | 2016 | Burak Yilmaz Co-Founder | 27 patents Targeted lipid-based delivery systems for oncoselective cancer therapeutics | — |
| 28 | Organogenesis Regenerative tissue innovations for advanced wound care and surgical solutions | $30M | 20 mo ago | 856 856 → 921 (+8%) · sector median +22% | 1985 | Gary Gillheeney CEO | 209 patents Collagen-based biomaterials for wound healing, tissue regeneration, and anti‑inflammatory assay kits. | — |
| 29 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 2 mo ago | 51 51 → 39 (-24%) · sector median +22% | 2015 | — | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 30 | Advanced Cell Technology Developer of stem-cell-based treatments in the field of regenerative medicine | $25M | 186 mo ago | — | 1994 | Ray Parvin CEO | 400 patents Molecular diagnostics and protein interaction assays using in situ hybridization and imaging | — |
| 31 | Minerva Biotechnologies Developer of cell therapy and antibodies to treat cancer | $19M | 32 mo ago | 24 | 1999 | — | 480 patents Therapeutic/diagnostic MUC1 antibodies, NME7 bacterial enzymes, stem‑cell dopaminergic neuron production | — |
| 32 | JURA Bio Developer of cell therapies for immunological disorders | $16M | 33 mo ago | 7 | 2017 | George Church Co-Founder | — | — |
| 33 | IMEL Developer of cell-based therapies to treat mitochondrial disorders | $15M | 56 mo ago | 5 | 2019 | Silvia Noiman Founder & CEO | — | — |
| 34 | Sentien Biotechnologies Developer of stem cell based device product for acute organ failure | $13M | 111 mo ago | 7 | 2008 | Biju Parekkadan Co-Founder | — | — |
| 35 | NKT Therapeutics Website setup tutorials for domain configuration and website appearance | $12M | 143 mo ago | 1 | 2008 | — | — | — |
| 36 | Geneius Developer of transformative personalized targeted T cell therapies for cancer treatment | $8M | 108 mo ago | 9 | 2015 | Alfred Slanetz Founder | — | — |
| 37 | Ernexa Therapeutics Developer of allogeneic iMSC-based cell therapies for cancer and autoimmune diseases | $7M | 15 mo ago | — | 1994 | Sanjeev Luther CEO & President | — | — |
| 38 | Ocata Therapeutics Stem cell-based therapies to treat dry age-related macular Degeneration (Dry AMD) and stargardt’s macular… | $3M | 130 mo ago | 37 | 1994 | — | — | — |
| 39 | Ypsilon Tx Developer of therapeutics for cancer treatment | $3M | 17 mo ago | — | 2022 | Dongxing Zha Co-Founder and CEO | — | — |
| 40 | BioXyTran Developing platform technologies in Glycovirology, Hypoxia, and Degenerative Diseases | $2M | 3 mo ago | 3 | 2008 | — | 2 patents Patents concentrated in health & consumer products | — |
| 41 | Alexis Bio Developer of cell therapies to treat common and rare diseases | $1M | 63 mo ago | 3 | 2016 | Jon Adkins Co-Founder | — | — |
| 42 | Guardian Bio Developer of cell-therapeutics for the treatment of cancer | $125K | 49 mo ago | 3 | 2022 | Richard Barrett Co-Founder and CSO | — | — |
Top 12 Cell Therapy companies in Massachusetts
#1
Public · Cambridge, Massachusetts · founded 2015 · 51 employees$26.4Mraised▾
Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.
- May 2026Post IPO$30M
- Nov 2022Post IPO$30M
- Dec 2016Series A$16.4M
- Jun 2015Seed$10M
#2
Series C · Newton, Massachusetts · founded 2015 · 24 employees$251.8Mraised▾
Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer. It offers ABC008 an anti-KLRG1 antibody for autoimmune muscle disease inclusion body myositis, T cell large granular lymphocytic leukemia, and mature T cell malignancies, ABC015 is a monoclonal antibody for cancer treatment.
- Feb 2025Series C$200M
- Aug 2023Series B$199.5M
- Jan 2021Series A$42M
- Aug 2019Grant (prize money)$164.1K
#3
Series A · Cambridge, Massachusetts · founded 2016 · 18 employees$35.4Mraised▾
Developer of mRNA therapeutics for immuno-oncology using deep learning technology. The company is developing platforms using deep learning algorithms and big data to design better mRNA therapeutics. The platform helps in three processes: codon-engineering, smart designing and non-immunogenic selection.
- Oct 2025Grant (prize money)$48M
- Feb 2022Series A$25M
- Jul 2021Seed$10M
- Oct 2018Grant (prize money)—
#4
Series C · Cambridge, Massachusetts · founded 2020 · 103 employees$264Mraised▾
Developer of B cell therapies for multiple therapeutic areas. The company uses proprietary autologous and allogeneic BeCM platforms across multiple therapeutic areas and progress pipeline candidates mainly on oncology and rare diseases. Also, it advances its platform into additional therapeutic areas including infectious disease, neurological conditions, and autoimmune disease.
- Jan 2025Series C$92M
- Oct 2024Series B$82M
- Apr 2022Series B$130M
- Oct 2020Series A$52M
#5
Series A · Boston, Massachusetts · founded 2022 · 21 employees$85Mraised▾
Developer of gene-based therapeutics for multiple diseases. It offers genome engineering and chromatin regulation technology for developing delivery methods for enzymes and drugs to provide targeted gene editing in-vivo.
- May 2025Series A$85M
#6
Acquired · Newton, Massachusetts · founded 2008 · 3 employees$2.2Mraised▾
Developing platform technologies in Glycovirology, Hypoxia, and Degenerative Diseases. It is focused on carbohydrate drug design to combat viruses and extend lifespan. It pioneers glycan-based technology, creating entry inhibitors that target viruses directly, potentially modulating the immune system. It is also developing oxygen therapeutic treatments for hypoxic conditions and necrosis prevention, targeting medical conditions like brain stroke, wound healing, and trauma.
- Mar 2026Post IPO$873.9K
- Mar 2023Post IPO$130K
- Aug 2022Post IPO$600K
- Nov 2019Post IPO$332.3K
#7
Series B · Natick, Massachusetts · founded 2021 · 44 employees$181.8Mraised▾
Developer of stem cell-based therapies to treat multiple diseases. The company has developed stem cell transplants by using targeted antibodies and increasing stem cell numbers by targeting self-renewal pathways. The company's pipeline includes therapeutic indications in hematologic malignancies, sickle cell disease, β-thalassemia, bone marrow failure diseases, and more.
- Oct 2024Series B$47.7M
- Feb 2023Series B$62.1M
- Sep 2021Series A$72M
#8
Series A · Cambridge, Massachusetts · founded 2017 · 43 employees$125Mraised▾
Developer of autologous cell therapies. The company has developed an AI-guided laser editing platform, single-cell laser processing, and robotics to generate autologous induced pluripotent stem cells for regenerative medicines for diseases like Parkinson’s, diabetes, and heart disease.
- Sep 2024Series A$25M
- Jan 2022Series A$80M
- Feb 2021Seed$16M
- Aug 2019Seed$2.5M
#9
Deadpooled · Cambridge, Massachusetts · founded 2021 · 50 employees$110.3Mraised▾
Developer of cell therapies for autoimmune and inflammatory disease. The company is developing regulatory T cells as targeted therapies that stop immune-mediated destruction and restore homeostasis. It is used for the treatment of progressive multiple sclerosis, type-1 diabetes, and inclusion body myositis.
- Aug 2024Series A—
- Dec 2023Series A$15.3M
- Jun 2021Series A$95M
#10
Series A · Cambridge, Massachusetts · founded 2019 · 15 employees$75Mraised▾
Developer of a synthetic biology platform for cell programming. It has a proprietary pluripotent stem cell differentiation technology platform TFome which helps in developing SuperCells for specific disease treatments.
- Sep 2024Series A$65M
#11
Series C · Cambridge, Massachusetts · founded 2015 · 80 employees$325Mraised▾
Developer of engineered cell and gene therapies for multiple diseases. The lead candidate cytoTIL15 is used for melanoma, HNSCC, cervical cancer, solid tumors, other candidates include cytoTILx-1 and cytoTILx-2, CD40L, and IL-12 for other disorders. The company's cytoDRiVE platform leverages drug-responsive domains to control protein function.
- Apr 2024Series C$160.5M
- Sep 2021Series B$115M
- Dec 2017Series A$49.5M
#12
Public · Canton, Massachusetts · founded 1985 · 856 employees$30Mraised▾
Regenerative tissue innovations for advanced wound care and surgical solutions. We are dedicated to empowering healing through regenerative medicine. Our focus lies in delivering clinicians a comprehensive range of regenerative tissue innovations and essential services. We specialize in advanced wound care and surgical & sports medicine solutions. We are committed to elevating the standard of care by providing transformative solutions. Our offerings include products like PuraPly and Affinity, alongside patient and provider support programs. We focus on innovation and regenerative solutions. We provide resources and support to healthcare professionals, ensuring they have access to the most advanced regenerative solutions available. We are committed to corporate social responsibility, ethics, and quality systems.
- Nov 2024Post IPO$130M
- May 2017Conventional Debt$20M
- Apr 2016Series C$30M
- Jan 2009Grant (prize money)$7.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cell Therapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Cell Therapy in Massachusetts is moving
A read on the academic research around Cell Therapy in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 132 papers.
MIT, MGH, and UMass Chan lead Massachusetts cell-therapy research—dominated by CAR-T and stem cell work—with a cautiously optimistic tone balancing breakthroughs against notable concerns.
- Massachusetts General Hospital91
- Massachusetts Institute of Technology26
- University of Massachusetts Chan Medical School12
- Massachusetts Eye and Ear Infirmary6
- University of Massachusetts Amherst2
- Chimeric antigen receptor1→4
- Transplantation2→4
- Bone marrow1→3
- Chimeric antigen receptor1→6
- Immune system1→6
- Immunotherapy1→5
- Adoptive cell transfer1→3
- Transplantation3→5
- Immunotherapy1→10
- Immune system2→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.